Boehringer Shoots For Schizophrenia With PDE9 Inhibitor, Ends Alzheimer's R&D
Boehringer's investigational drug, BI 409306, is the second big pharma PDE9 inhibitor to fail in Alzheimer's clinical trials; Eisai is still standing with a Phase I compound but the odds are not in its favor.
You may also be interested in...
Imara has raised $63m to pursue its PDE9 inhibitor for sickle cell disease, and hopes to broaden the Phase II drug candidate into related blood disorders such as beta thalassemia.
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
US biotech vTv Therapeutics has again reported disappointing top-line Phase III clinical study results for its potential Alzheimer's disease therapy, azeliragon, but believes it has identified a possible path to continued development.